Lung immune prognostic index as a prognostic predictor in patients with advanced small cell lung cancer
Abstract
Aims: Identifying prognostic markers in advanced small-cell lung cancer (A-SCLC) patients is important. Therefore, our study aimed to evaluate the prognostic value of pretreatment lung immune prognostic index (LIPI) in A-SCLC.
Methods: This was a retrospective and observational study of A-SCLC patients treated with platinum plus etoposide chemotherapy as first-line treatment. The association of LIPI with progression-free survival (PFS) and overall survival (OS) was analysed.
Results: One hundred eighteen patients were included in this study and divided into three groups LIPI 0 (n=27, 22.9%), LIPI 1 (n=57, 48.3%) and LIPI 2 (n=34, 28.8%). The median PFS of LIPI groups (0/1/2) was 8.9 (95% CI 3.83-13.96), 8 (95% CI 6.41-9.58), and 5.6 (95% CI 4.60-6.60) months, respectively (p=0.1) The median OS of LIPI groups (0/1/2) was 12 (95% CI 9.11-14.88), 10.1 (95% CI 9.16-11.03), and 7.7 (95% CI 6.55-8.84) months, respectively (p=0.02). Cox regression analysis revealed that LIPI 2 score was an independent risk factor for both PFS (HR 1.839, 95% CI: 1.075-3.144, p=0.02) and OS (HR 1.757, 95% CI: 1.006-3.071, p=0.04).
Conclusion: LIPI score can be used as a simple and easily accessible marker to predict prognosis for A-SCLC patients.
Keywords
Lung immune prognostic index (LIPI) prognostic marker small-cell lung cancer (SCLC) systemic inflammatory indexes
Supporting Institution
None
Project Number
None
Thanks
none
References
- Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin 2014; 24: 257–66.
- Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S. New insights into small-cell lung cancer development and therapy. Cell Biol Int 2020; 44: 1564–76.
- Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers 2021; 7: 3.
- Franco F, Carcereny E, Guirado M, et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: data from the thoracic tumor registry. PLoS One 2021; 16: e02511761.
- Dingemans AMC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 839–53.
- Sun B, Hou Q, Liang Y, et al. Prognostic ability of lung immune prognostic index in limited‑stage small cell lung cancer. BMC Cancer 2022; 22: 1233.
- Qi WX, Xiang Y, Zhao S, Chen J. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother 2021; 70: 3199–206.
- Huang L, Han H, Zhou L, et al. Evaluation of the lung immune prognostic index in non-small cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis. Front Oncol 2021; 11: 670230.
- Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.
- Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: Small cell lung cancer, Version 2.2018. J Natl Compr Canc Netw 2018; 16: 1171–82.
- Zhang Q, Gong X, Sun L, Miao L, Zhou Y. The predictive value of pretreatment lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a meta-analysis. Front Oncol 2022; 12: 791496.
- Jiang S, Wang S, Wang Q, et al. Systemic inflammation response index (SIRI) independently predicts survival in advanced lung adenocarcinoma patients treated with first-generation EGFR-TKIs. Cancer Manag Res 2021; 13: 1315–22.
- Sonehara K, Tateishi K, Komatsu M, Yamamoto H, Hanaoka M. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thorac Cancer 2020; 11: 1578–86.
- SchnÖller L, KÄsmann L, Taugner J, Abdo R, Eze C, Manapov F. Prognostic role of lung immune scores for prediction of survival in limited-stage small cell lung cancer. In Vivo 2021; 35: 929–35.
- Chen J, Wei S, Zhao T, Zhang X, Wang Y, Zhang X. Clinical significance of serum biomarkers in stage IV non-small-cell lung cancer treated with PD-1 inhibitors: LIPI score, NLR, dNLR, LMR, and PAB. Dis Markers 2022; 2022: 7137357.
- Li L, Pi C, Yan X, et al. Prognostic value of the pretreatment lung immune prognostic index in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors plus chemotherapy. Front Oncol 2021; 11: 697865.
- Qi W, Zhao S, Chen J. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy. Cancer Biomarkers 2021; 31: 177–85.
- Minici R, Siciliano MA, Ammendola M, et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations. Cancers (Basel) 2022; 15: 257.
- Yang J, Deng M, Bi M, Wang Y, Qiao X. Zhang S. Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer. Futur Sci OA 2022; 8: FSO798.
- Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med 2017; 15: 221.
- Zhou Q, Deng G, Wang Z, Dai G. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. Front Surg 2023; 9: 1002075.
Abstract
Project Number
None
References
- Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin 2014; 24: 257–66.
- Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S. New insights into small-cell lung cancer development and therapy. Cell Biol Int 2020; 44: 1564–76.
- Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers 2021; 7: 3.
- Franco F, Carcereny E, Guirado M, et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: data from the thoracic tumor registry. PLoS One 2021; 16: e02511761.
- Dingemans AMC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 839–53.
- Sun B, Hou Q, Liang Y, et al. Prognostic ability of lung immune prognostic index in limited‑stage small cell lung cancer. BMC Cancer 2022; 22: 1233.
- Qi WX, Xiang Y, Zhao S, Chen J. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother 2021; 70: 3199–206.
- Huang L, Han H, Zhou L, et al. Evaluation of the lung immune prognostic index in non-small cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis. Front Oncol 2021; 11: 670230.
- Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.
- Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: Small cell lung cancer, Version 2.2018. J Natl Compr Canc Netw 2018; 16: 1171–82.
- Zhang Q, Gong X, Sun L, Miao L, Zhou Y. The predictive value of pretreatment lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a meta-analysis. Front Oncol 2022; 12: 791496.
- Jiang S, Wang S, Wang Q, et al. Systemic inflammation response index (SIRI) independently predicts survival in advanced lung adenocarcinoma patients treated with first-generation EGFR-TKIs. Cancer Manag Res 2021; 13: 1315–22.
- Sonehara K, Tateishi K, Komatsu M, Yamamoto H, Hanaoka M. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thorac Cancer 2020; 11: 1578–86.
- SchnÖller L, KÄsmann L, Taugner J, Abdo R, Eze C, Manapov F. Prognostic role of lung immune scores for prediction of survival in limited-stage small cell lung cancer. In Vivo 2021; 35: 929–35.
- Chen J, Wei S, Zhao T, Zhang X, Wang Y, Zhang X. Clinical significance of serum biomarkers in stage IV non-small-cell lung cancer treated with PD-1 inhibitors: LIPI score, NLR, dNLR, LMR, and PAB. Dis Markers 2022; 2022: 7137357.
- Li L, Pi C, Yan X, et al. Prognostic value of the pretreatment lung immune prognostic index in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors plus chemotherapy. Front Oncol 2021; 11: 697865.
- Qi W, Zhao S, Chen J. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy. Cancer Biomarkers 2021; 31: 177–85.
- Minici R, Siciliano MA, Ammendola M, et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations. Cancers (Basel) 2022; 15: 257.
- Yang J, Deng M, Bi M, Wang Y, Qiao X. Zhang S. Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer. Futur Sci OA 2022; 8: FSO798.
- Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med 2017; 15: 221.
- Zhou Q, Deng G, Wang Z, Dai G. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. Front Surg 2023; 9: 1002075.
Details
| Primary Language | English |
|---|---|
| Subjects | Chest Diseases, Health Care Administration |
| Journal Section | Research Articles |
| Authors | |
| Project Number | None |
| Early Pub Date | July 26, 2023 |
| Publication Date | July 28, 2023 |
| Published in Issue | Year 2023 Volume: 5 Issue: 3 |
TR DİZİN ULAKBİM and International Indexes (1b)
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show
Journal Indexes and Platforms:
TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.The indexes of the journal's are;
|
|
|
|
The platforms of the journal's are;
|
|
|
|
The indexes/platforms of the journal are;
TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit
EBSCO, DOAJ, OAJI is under evaluation.
Journal articles are evaluated as "Double-Blind Peer Review"